Is Ionis Pharmaceuticals Stock a Good Investment?
Ionis Pharmaceuticals Investment Advice | IONS |
- Examine Ionis Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Ionis Pharmaceuticals' leadership team and their track record. Good management can help Ionis Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Ionis Pharmaceuticals' business and its evolving consumer preferences.
- Compare Ionis Pharmaceuticals' performance and market position to its competitors. Analyze how Ionis Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Ionis Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Ionis Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Ionis Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Ionis Pharmaceuticals is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Ionis Pharmaceuticals Stock
Researching Ionis Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 101.16. Ionis Pharmaceuticals recorded a loss per share of 2.44. The entity had not issued any dividends in recent years.
To determine if Ionis Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ionis Pharmaceuticals' research are outlined below:
| Ionis Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 787.65 M. Net Loss for the year was (366.29 M) with loss before overhead, payroll, taxes, and interest of (257.87 M). | |
| Ionis Pharmaceuticals currently holds about 2.04 B in cash with (307.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.36. | |
| Ionis Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Lou Gehrigs Disease Pipeline Landscape Report 2024 Therapeutic Assessment of 80 Drugs by Product Type, Stage, Route of Administration, and Molecule Type |
Ionis Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ionis Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ionis Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Ionis Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Ionis Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2018-02-27 | 2017-12-31 | 0.01 | 0.02 | 0.01 | 100 | ||
2013-05-07 | 2013-03-31 | -0.02 | -0.03 | -0.01 | 50 | ||
2009-08-06 | 2009-06-30 | -0.02 | -0.03 | -0.01 | 50 | ||
2018-05-04 | 2018-03-31 | -0.03 | -0.01 | 0.02 | 66 | ||
2017-05-09 | 2017-03-31 | 0.05 | 0.03 | -0.02 | 40 | ||
2016-11-09 | 2016-09-30 | 0.08 | 0.06 | -0.02 | 25 | ||
2012-02-29 | 2011-12-31 | -0.18 | -0.2 | -0.02 | 11 | ||
2014-11-07 | 2014-09-30 | -0.2 | -0.23 | -0.03 | 15 |
Know Ionis Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ionis Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ionis Pharmaceuticals backward and forwards among themselves. Ionis Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Ionis Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Pictet Asset Manangement Sa | 2024-06-30 | 2.4 M | Orbimed Advisors, Llc | 2024-06-30 | 2.4 M | Artisan Partners Limited Partnership | 2024-09-30 | 2.2 M | Deep Track Capital, Lp | 2024-09-30 | 2.2 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2 M | Macquarie Group Ltd | 2024-06-30 | 1.9 M | Clearbridge Advisors, Llc | 2024-09-30 | 1.7 M | Bvf Inc | 2024-09-30 | 1.5 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.4 M | Fmr Inc | 2024-09-30 | 22.5 M | Vanguard Group Inc | 2024-09-30 | 15.1 M |
Ionis Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.37 B.Market Cap |
|
Ionis Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.12) | (0.13) | |
| Return On Capital Employed | (0.14) | (0.15) | |
| Return On Assets | (0.12) | (0.13) | |
| Return On Equity | (0.95) | (0.99) |
Determining Ionis Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Ionis Pharmaceuticals is a good buy. For example, gross profit margin measures Ionis Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ionis Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Ionis Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Ionis Pharmaceuticals. Check Ionis Pharmaceuticals' Beneish M Score to see the likelihood of Ionis Pharmaceuticals' management manipulating its earnings.
Evaluate Ionis Pharmaceuticals' management efficiency
Ionis Pharmaceuticals has return on total asset (ROA) of (0.0725) % which means that it has lost $0.0725 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7338) %, meaning that it created substantial loss on money invested by shareholders. Ionis Pharmaceuticals' management efficiency ratios could be used to measure how well Ionis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.13 in 2024. Return On Capital Employed is likely to drop to -0.15 in 2024. At this time, Ionis Pharmaceuticals' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 365.6 M in 2024, whereas Intangible Assets are likely to drop slightly above 24.2 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.70 | 2.22 | |
| Tangible Book Value Per Share | 2.70 | 1.97 | |
| Enterprise Value Over EBITDA | (36.08) | (37.88) | |
| Price Book Value Ratio | 18.73 | 17.80 | |
| Enterprise Value Multiple | (36.08) | (37.88) | |
| Price Fair Value | 18.73 | 17.80 | |
| Enterprise Value | 7.5 B | 7.8 B |
Leadership effectiveness at Ionis Pharmaceuticals is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 0.392 |
Basic technical analysis of Ionis Stock
As of the 25th of November, Ionis Pharmaceuticals retains the Market Risk Adjusted Performance of (0.53), standard deviation of 2.63, and Risk Adjusted Performance of (0.13). Ionis Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Ionis Pharmaceuticals variance and skewness to decide if Ionis Pharmaceuticals is priced fairly, providing market reflects its last-minute price of 34.01 per share. Given that Ionis Pharmaceuticals has information ratio of (0.23), we strongly advise you to confirm Ionis Pharmaceuticals's regular market performance to make sure the company can sustain itself at a future point.Ionis Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ionis Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ionis Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ionis Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ionis Pharmaceuticals' Outstanding Corporate Bonds
Ionis Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ionis Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ionis bonds can be classified according to their maturity, which is the date when Ionis Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US462222AB68 Corp BondUS462222AB68 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Ionis Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Ionis Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | (0.53) | |||
| Mean Deviation | 1.85 | |||
| Coefficient Of Variation | (558.43) | |||
| Standard Deviation | 2.63 | |||
| Variance | 6.92 | |||
| Information Ratio | (0.23) | |||
| Jensen Alpha | (0.59) | |||
| Total Risk Alpha | (0.90) | |||
| Treynor Ratio | (0.54) | |||
| Maximum Drawdown | 15.6 | |||
| Value At Risk | (4.12) | |||
| Potential Upside | 3.09 | |||
| Skewness | (1.55) | |||
| Kurtosis | 5.77 |
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | (0.53) | |||
| Mean Deviation | 1.85 | |||
| Coefficient Of Variation | (558.43) | |||
| Standard Deviation | 2.63 | |||
| Variance | 6.92 | |||
| Information Ratio | (0.23) | |||
| Jensen Alpha | (0.59) | |||
| Total Risk Alpha | (0.90) | |||
| Treynor Ratio | (0.54) | |||
| Maximum Drawdown | 15.6 | |||
| Value At Risk | (4.12) | |||
| Potential Upside | 3.09 | |||
| Skewness | (1.55) | |||
| Kurtosis | 5.77 |
Consider Ionis Pharmaceuticals' intraday indicators
Ionis Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ionis Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Ionis Pharmaceuticals Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 17th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Ionis Stock media impact
Far too much social signal, news, headlines, and media speculation about Ionis Pharmaceuticals that are available to investors today. That information is available publicly through Ionis media outlets and privately through word of mouth or via Ionis internal channels. However, regardless of the origin, that massive amount of Ionis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Ionis Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ionis Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ionis Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ionis Pharmaceuticals alpha.
Ionis Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Ionis Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Ionis Pharmaceuticals Historical Investor Sentiment
Investor biases related to Ionis Pharmaceuticals' public news can be used to forecast risks associated with an investment in Ionis. The trend in average sentiment can be used to explain how an investor holding Ionis can time the market purely based on public headlines and social activities around Ionis Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ionis Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ionis Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Ionis Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Ionis Pharmaceuticals.
Ionis Pharmaceuticals Corporate Management
| Brett Monia | Sr. VP of Drug Discovery and Corporate Devel. | Profile | |
| Patrick Esq | Chief VP | Profile | |
| Eric Swayze | Executive Research | Profile | |
| Hayley Soffer | Vice Communications | Profile |
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.